NYSE:MED - Medifast Stock Price, News, & Analysis

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast declared a quarterly dividend on Thursday, March 14th. Investors of record on Friday, March 29th will be paid a dividend of $0.75 per share on Tuesday, May 7th. This represents a $3.00 annualized dividend and a yield of 2.22%. The ex-dividend date is Thursday, March 28th. View Medifast's Dividend History.

Medifast Inc (NYSE:MED) released its quarterly earnings results on Tuesday, February, 26th. The specialty retailer reported $1.30 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.21 by $0.09. The specialty retailer had revenue of $145.80 million for the quarter, compared to analyst estimates of $141.86 million. Medifast had a return on equity of 51.04% and a net margin of 11.14%. The business's revenue was up 86.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.60 EPS. View Medifast's Earnings History.

Medifast is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Medifast.

Medifast updated its FY19 earnings guidance on Tuesday, February, 26th. The company provided earnings per share (EPS) guidance of $6.45-6.65 for the period, compared to the Thomson Reuters consensus estimate of $5.86. The company issued revenue guidance of $700-720 million, compared to the consensus revenue estimate of $653.45 million.Medifast also updated its FY 2019 guidance to $6.45-6.65 EPS.

2 brokers have issued 12-month target prices for Medifast's shares. Their forecasts range from $216.00 to $249.00. On average, they expect Medifast's stock price to reach $232.50 in the next twelve months. This suggests a possible upside of 71.8% from the stock's current price. View Analyst Price Targets for Medifast.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medifast.

Media headlines about MED stock have been trending neutral this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Medifast earned a news sentiment score of 0.4 on InfoTrie's scale. They also gave press coverage about the specialty retailer a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.

Some companies that are related to Medifast include MCCORMICK & CO /SH (MKC), Greencore Group (GNCGY), Farmer Bros (FARM), China Marine Food Group (CMFO) and Jammin Java (JAMN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Boeing (BA), Adobe (ADBE), Mastercard (MA), UnitedHealth Group (UNH), Paypal (PYPL), Align Technology (ALGN) and salesforce.com (CRM).

Medifast's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.23%), Dimensional Fund Advisors LP (5.50%), Acadian Asset Management LLC (3.62%), MERIAN GLOBAL INVESTORS UK Ltd (2.54%), Principal Financial Group Inc. (1.80%) and Bank of New York Mellon Corp (1.63%). Company insiders that own Medifast stock include Carl E Sassano, Charles P Connolly, Constance J Hallquist, Daniel R Chard, Glenn W Welling, Jeremy John Martin, Michael A Hoer, Michael C Macdonald, Ralph Rushton, Scott Schlackman and Simon TP Ridgway. View Institutional Ownership Trends for Medifast.

MED stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, O Shaughnessy Asset Management LLC, Prudential Financial Inc., KBC Group NV, Dimensional Fund Advisors LP, SG Americas Securities LLC, Nisa Investment Advisors LLC and Hsbc Holdings PLC. Company insiders that have sold Medifast company stock in the last year include Carl E Sassano, Charles P Connolly, Constance J Hallquist and Scott Schlackman. View Insider Buying and Selling for Medifast.

MED stock was purchased by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Millennium Management LLC, Norges Bank, Intrinsic Edge Capital Management LLC, Assenagon Asset Management S.A., Bank of America Corp DE, Principal Financial Group Inc. and First Trust Advisors LP. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard, Michael A Hoer and Simon TP Ridgway. View Insider Buying and Selling for Medifast.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MED stock can currently be purchased for approximately $135.36.

Medifast has a market capitalization of $1.61 billion and generates $501 million in revenue each year. The specialty retailer earns $55.79 million in net income (profit) each year or $4.62 on an earnings per share basis.

The official website for Medifast is http://www.medifast1.com.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]